Allogene Therapeutics, Inc. (ALLO)
Market Cap | 626.35M |
Revenue (ttm) | 65,000 |
Net Income (ttm) | -293.56M |
Shares Out | 208.78M |
EPS (ttm) | -1.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,534,255 |
Open | 2.990 |
Previous Close | 2.910 |
Day's Range | 2.860 - 3.050 |
52-Week Range | 2.010 - 5.780 |
Beta | 0.85 |
Analysts | Buy |
Price Target | 10.51 (+250.33%) |
Earnings Date | Jul 31, 2024 |
About ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 fo... [Read more]
Financial Performance
In 2023, ALLO's revenue was $95,000, a decrease of -39.10% compared to the previous year's $156,000. Losses were -$327.27 million, -3.86% less than in 2022.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is $10.51, which is an increase of 250.33% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/m/u/press14-2504606.jpg)
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
![](https://cdn.snapi.dev/images/v1/g/l/press7-2487874.jpg)
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., June 20, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of alloge...
![](https://cdn.snapi.dev/images/v1/e/k/press1-2445347.jpg)
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
![](https://cdn.snapi.dev/images/v1/o/i/press11-2428204.jpg)
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
![](https://cdn.snapi.dev/images/v1/d/u/press2-2427995.jpg)
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
![](https://cdn.snapi.dev/images/v1/d/a/conf11-2411899.jpg)
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
![](https://cdn.snapi.dev/images/v1/d/g/press12-2394050.jpg)
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
![](https://cdn.snapi.dev/images/v1/0/p/conf12-2362958.jpg)
Allogene Therapeutics Announces Q2 Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
![](https://cdn.snapi.dev/images/v1/8/8/press8-2325267.jpg)
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
![](https://cdn.snapi.dev/images/v1/i/e/press13-2319855.jpg)
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of al...
![](https://cdn.snapi.dev/images/v1/b/w/conf16-2308393.jpg)
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET
![](https://cdn.snapi.dev/images/v1/p/w/press10-2298410.jpg)
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/x/8/press9-2280311.jpg)
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/3/e/conf18-2231419.jpg)
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/b/a/bank6-2218082.jpg)
Allogene to cut 22% of its workforce
Allogene Therapeutics said on Friday it will cut 22% of its workforce as part of a clinical development strategy aimed at prioritizing its product pipeline.
![](https://cdn.snapi.dev/images/v1/o/8/press10-2217315.jpg)
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (Al...
![](https://cdn.snapi.dev/images/v1/b/j/press9-2217257.jpg)
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/r/v/conf6-2215434.jpg)
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/a/p/press1-2190203.jpg)
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/n/h/conf13-2179655.jpg)
Allogene Therapeutics Announces Participation in December Investor Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/a/i/press9-2139470.jpg)
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/c/d/press10-2139471.jpg)
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/c/7/press10-2137485.jpg)
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/n/l/conf1-2127814.jpg)
Allogene Therapeutics Announces Participation in November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
![](https://cdn.snapi.dev/images/v1/y/n/conf13-2122619.jpg)
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...